Long-Term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Children and Adolescents With HIV-1 Aged 2 to

Conference Reports for NATAP

13th IAS Conference on HIV Science
IAS 2026
July 26-31 Rio, Brazil


Long-Term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Children and Adolescents With HIV-1 Aged 2 to < 18 Years

	IAS 2026 Rio, Brazil